Greetings from Top Management

As a specialized pharmaceutical company, Santen continues to make utmost efforts to contribute to ophthalmic treatment around the world.

Akira Kurokawa Chairman and Chief Executive Officer Photo

Guided by Santen’s Values, the Santen Group focuses our efforts on the ophthalmic field to contribute to patients and their loved ones. As a specialized ophthalmic company, we strive to advance treatments by delivering innovative products and services to patients and medical professionals worldwide.

Globally, there are still many countries and regions where ophthalmic treatments are not sufficiently reaching patients. There are also fields in which available treatments are not sufficiently meeting medical needs, particularly for the treatment of glaucoma and retinal disorders. I believe that Santen has a great responsibility and opportunity to address such unmet needs while meeting the expectation of all stakeholders, in particular patients and their loved ones.

Akira Kurokawa Chairman and Chief Executive Officer

Shigeo Taniuchi President and Chief Operating Officer Photo

As a specialized pharmaceutical company in ophthalmology, Santen aims to contribute to patients’ quality of vision (QOV) worldwide, by developing our business around the globe.

To realize our long-term strategic vision, we are investing in future growth including R&D and the expansion of our business platforms, particularly in the rapidly growing markets of Asia and EMEA, as well as Japan, where we are further building on our very strong position. We are enhancing our business execution capabilities amid accelerating globalization as toward realizing our vision and long-term strategy to 2020 and beyond.

We ask all of our stakeholders for their continued support going forward.

Shigeo Taniuchi President and Chief Operating Officer